Validation of the European Association for the Study of the Liver algorithm for the noninvasive diagnosis of advanced fibrosis in metabolic-dysfunction associated steatotic liver disease  

作　　者：Markos Kalligeros Emmanuel A.Tsochatzis 

机构地区：[1]Division of Internal Medicine,Warren Alpert Medical School of Brown University,Rhode Island Hospital,Providence,RI,USA [2]UCL Institute for Liver and Digestive Health,Royal Free Hospital and UCL,London,UK [3]Sheila Sherlock Liver Unit,Royal Free Hospital,London,UK

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第2期311-313,共3页肝胆外科与营养（英文）

摘　　要：Metabolic-dysfunction associated steatotic liver disease(MASLD),formerly known as non-alcoholic fatty liver disease(NAFLD)(1),is characterized by the accumulation of fat in the liver cells,independent of excessive alcohol consumption and has emerged as the most prevalent chronic liver condition in Western countries,underscoring a significant public health concern(2).The progression of MASLD to advanced fibrosis,marked by excessive extracellular matrix deposition and scar tissue formation,is a critical stage in MASLD natural history that significantly increases the risk of liver-related complications mortality(3).Non-invasive tests(NITs),such as liver stiffness measurement(LSM)with transient elastography(TE)and serum biomarkers,have gained prominence for assessing liver fibrosis in patients with suspected/confirmed NAFLD,offering a safer and less invasive alternative to liver biopsy(4).

关 键 词：FIBROSCAN enhanced liver fibrosis(ELF) fibrosis-4(FIB-4) cirrhosis metabolic-dysfunction associated steatotic liver disease(MASLD) 

分 类 号：R575.5[医药卫生—消化系统]